Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00781742 · ClinicalTrials.gov registry record · Phase 2

AZD6765 Severe Major Depressive Disorder (MDD) IV

A Phase 2 study of Major Depressive Disorder, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
152
Enrollment target
20
Study locations

NCT00781742 is a Phase 2 study of Major Depressive Disorder that has completed, run by AstraZeneca. The registered enrollment target is 152 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00781742, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be gathered on how well AZD6765 is tolerated, investigate the levels of AZD6765 and the levels of the current depression medication in the blood. In addition, the research staff will determine if AZD6765 has any mood or calming effects (how you feel).

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG Placebo
  • DRUG AZD6765

Study Locations (20)

California

  • Research Site - Los Angeles
  • Research Site - Orange
  • Research Site - San Diego
  • Research Site - Santa Ana

Florida

  • Research Site - Boca Raton
  • Research Site - Gainsville
  • Research Site - Hollywood
  • Research Site - Jacksonville

Connecticut

  • Research Site - Hartford
  • Research Site - New Haven

Georgia

  • Research Site - Atlanta
  • Research Site - Roswell

Illinois

  • Research Site - Hoffman Estates
  • Research Site - Joliet

Louisiana

  • Research Site - Lake Charles
  • Research Site - Shreveport

Arkansas

  • Research Site - Little Rock

Kansas

  • Research Site - Overland Park

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2008-10
Est. Completion 2010-03
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00781742

The ClinicalTrials.gov registry entry for NCT00781742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00781742 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00781742 about?

NCT00781742 is a clinical study titled "AZD6765 Severe Major Depressive Disorder (MDD) IV". The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be gathered on how well AZD6765 is tolerated, investigate the levels of AZD6765 and the levels of the cur...

What is the current status of trial NCT00781742?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2008-10. Estimated completion is 2010-03.

What conditions does trial NCT00781742 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT00781742?

The interventions under investigation include: Placebo (DRUG), AZD6765 (DRUG).

Who is sponsoring clinical trial NCT00781742?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00781742 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.